<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Noncoding RNA</journal-id><journal-id journal-id-type="iso-abbrev">Noncoding RNA</journal-id><journal-id journal-id-type="publisher-id">ncrna</journal-id><journal-title-group><journal-title>Non-Coding RNA</journal-title></journal-title-group><issn pub-type="epub">2311-553X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407590</article-id><article-id pub-id-type="pmc">PMC12101234</article-id>
<article-id pub-id-type="doi">10.3390/ncrna11030032</article-id><article-id pub-id-type="publisher-id">ncrna-11-00032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>In Silico Prioritization of STAT1 3&#x02032; UTR SNPs Identifies rs190542524 as a miRNA-Linked Variant with Potential Oncogenic Impact</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kamal</surname><given-names>Ebtihal</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Telonis</surname><given-names>Aristeidis G.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ncrna-11-00032">Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdulaziz University, Al Kharj 16278, Saudi Arabia; <email>e.kamal@psau.edu.sa</email></aff><pub-date pub-type="epub"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>11</volume><issue>3</issue><elocation-id>32</elocation-id><history><date date-type="received"><day>07</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the author.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Single-nucleotide polymorphisms (SNPs) are associated with multiple disorders and various cancer types. In the context of cancer, alterations within non-coding regions, specifically 3&#x02032; untranslated regions (3&#x02032; UTR), have proven substantially important. Methods: In this study, we utilized various bioinformatics tools to examine the effect of SNPs in the 3&#x02032; UTR. We retrieved the 3&#x02032; UTR SNPs of the Signal Transducer and Activator of Transcription 1 (STAT1) gene from the National Centre for Biotechnology Information (NCBI) website. Next, we employed the Polymorphism in miRNAs and their corresponding target sites (PolymiRTS) database to predict the 3&#x02032; UTR SNPs that create new microRNA (miRNA) binding sites and their respective miRNAs. The effect of the 3&#x02032; UTR SNPs on the messenger RNA structure was studied using RNAfold server. We used Cscape tool to predict the oncogenic 3&#x02032; UTR SNPs. Then, we submitted the miRNAs to the miRNet database to visualize the miRNA-miRNAs&#x02019; target genes interaction, for which gene enrichment analysis was performed using ShinyGO. Protein&#x02013;protein interactions were conducted using the STRING database. We conducted miRNA enrichment analysis utilizing miRPathDB, subsequently performing miRNA differential expression analysis through oncoMIR, and the StarBase database. The survival analysis of the upregulated miRNAs in cancer was investigated using the Kaplan&#x02013;Meier Plotter. Result: Twelve SNPs were predicted to create new miRNA binding sites. Two of them, rs188557905 and rs190542524, were predicted to destabilize the mRNA structures. We predicted rs190542524, rs11305, rs186033487, and rs188557905 to be oncogenic 3&#x02032; UTR SNPs, with high-confidence predictions and scores &#x0003e; 0.5. Using miRNAs&#x02019; target genes enrichment analysis, this study indicated that the miRNA target genes were more likely to be involved in cancer-related pathways. Our comprehensive analysis of miRNAs, their functional enrichment, their expression in various types of cancer, and the correlation between miRNA expression and survival outcome yielded these results. Our research shows that the oncogenic 3&#x02032; UTR SNP rs190542524 creates a new binding site for the oncogenic miRNA hsa-miR-136-5p. This miRNA is significantly upregulated in BLCA, LUSC, and STAD and is linked to poor survival. Additionally, rs114360225 creates a new binding site for hsa-miR-362-3p, influencing LIHC. Conclusions: These analyses suggest that these 3&#x02032; UTR SNPs may have a functional impact on the STAT1 gene&#x02019;s regulation through their predicted effect on miRNA binding sites. Future experimental validation could establish their potential role in the diagnosis and treatment of various diseases, including cancer.</p></abstract><kwd-group><kwd>3&#x02032; UTR SNP</kwd><kwd>UTR</kwd><kwd>STAT1</kwd><kwd>miRNA</kwd><kwd>bioinformatics</kwd></kwd-group><funding-group><award-group><funding-source>Prince Sattam bin Abdulaziz University</funding-source><award-id>2024/03/28313</award-id></award-group><funding-statement>This study is supported via funding from Prince Sattam bin Abdulaziz University Grant Number 2024/03/28313.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-ncrna-11-00032"><title>1. Introduction</title><p>Signal Transducer and Activator of Transcription 1 (STAT1) is a dormant transcription factor in the cytoplasm that plays an important role in the interferon signaling pathway [<xref rid="B1-ncrna-11-00032" ref-type="bibr">1</xref>,<xref rid="B2-ncrna-11-00032" ref-type="bibr">2</xref>]. It belongs to a protein family comprising transcription factors crucial for regulating diverse intracellular processes, including proliferation, differentiation, apoptosis, and angiogenesis [<xref rid="B3-ncrna-11-00032" ref-type="bibr">3</xref>,<xref rid="B4-ncrna-11-00032" ref-type="bibr">4</xref>,<xref rid="B5-ncrna-11-00032" ref-type="bibr">5</xref>]. The JAK-STAT pathway, which includes STAT1, is activated in response to type I, type II interferons, and many other cytokines [<xref rid="B2-ncrna-11-00032" ref-type="bibr">2</xref>,<xref rid="B6-ncrna-11-00032" ref-type="bibr">6</xref>,<xref rid="B7-ncrna-11-00032" ref-type="bibr">7</xref>].</p><p>A wide range of diverse diseases have been linked to dysregulated STAT1 protein and defects in the JAK-STAT signaling pathway, emphasizing the importance of this pathway in maintaining cellular integrity [<xref rid="B8-ncrna-11-00032" ref-type="bibr">8</xref>,<xref rid="B9-ncrna-11-00032" ref-type="bibr">9</xref>,<xref rid="B10-ncrna-11-00032" ref-type="bibr">10</xref>].</p><p>The function and significance of STAT1 in cancer biology have been studied for a long time [<xref rid="B11-ncrna-11-00032" ref-type="bibr">11</xref>]. However, STAT1&#x02019;s role in cancer biology as well as the mechanism underlying its tumor-suppressive or oncogenic properties remain unclear [<xref rid="B11-ncrna-11-00032" ref-type="bibr">11</xref>]. Most data indicate that STAT1 activation has a tumor suppressor function in cancer cells [<xref rid="B11-ncrna-11-00032" ref-type="bibr">11</xref>,<xref rid="B12-ncrna-11-00032" ref-type="bibr">12</xref>,<xref rid="B13-ncrna-11-00032" ref-type="bibr">13</xref>,<xref rid="B14-ncrna-11-00032" ref-type="bibr">14</xref>]. While other clinical studies and experimental results indicate that STAT1 has tumor-promoting properties [<xref rid="B15-ncrna-11-00032" ref-type="bibr">15</xref>,<xref rid="B16-ncrna-11-00032" ref-type="bibr">16</xref>]. Additional research indicates that STAT1 can act as both a tumor suppressor and an oncoprotein in cells with specific malignant phenotypes [<xref rid="B11-ncrna-11-00032" ref-type="bibr">11</xref>,<xref rid="B17-ncrna-11-00032" ref-type="bibr">17</xref>].</p><p>MicroRNA (miRNA) is a small, noncoding RNA with 20&#x02013;22 nucleotides [<xref rid="B18-ncrna-11-00032" ref-type="bibr">18</xref>,<xref rid="B19-ncrna-11-00032" ref-type="bibr">19</xref>]. It binds to the 3&#x02032; untranslated region (3&#x02032; UTR) of messenger RNA (mRNA), inhibiting translation and ultimately resulting in mRNA degradation [<xref rid="B20-ncrna-11-00032" ref-type="bibr">20</xref>,<xref rid="B21-ncrna-11-00032" ref-type="bibr">21</xref>,<xref rid="B22-ncrna-11-00032" ref-type="bibr">22</xref>].</p><p>A single miRNA can modulate the expression of numerous mRNAs within a cell by binding to the specific 3&#x02032; UTR binding sites of the target mRNA [<xref rid="B22-ncrna-11-00032" ref-type="bibr">22</xref>]. Multiple binding sites for the same miRNA within 3&#x02032; UTRs can significantly amplify its regulatory effect [<xref rid="B23-ncrna-11-00032" ref-type="bibr">23</xref>].</p><p>Single-nucleotide polymorphisms (SNPs) are gene variations that have a higher frequency than other variations, such as insertions, deletions, and copy number variations, which can influence gene function and contribute to diversity in phenotypes and disease susceptibility [<xref rid="B24-ncrna-11-00032" ref-type="bibr">24</xref>].</p><p>SNPs modulate gene expression via various mechanisms and can be located in 5&#x02032; UTR and 3&#x02032; UTRs [<xref rid="B25-ncrna-11-00032" ref-type="bibr">25</xref>]. The 5&#x02032; UTR comprises genetic components that modulate gene expression [<xref rid="B26-ncrna-11-00032" ref-type="bibr">26</xref>]. Polymorphisms in 5&#x02032; UTRs are associated with numerous human diseases [<xref rid="B27-ncrna-11-00032" ref-type="bibr">27</xref>,<xref rid="B28-ncrna-11-00032" ref-type="bibr">28</xref>,<xref rid="B29-ncrna-11-00032" ref-type="bibr">29</xref>,<xref rid="B30-ncrna-11-00032" ref-type="bibr">30</xref>] due to their regulation of mRNA processing, transport, stability, and translation [<xref rid="B27-ncrna-11-00032" ref-type="bibr">27</xref>,<xref rid="B31-ncrna-11-00032" ref-type="bibr">31</xref>].</p><p>SNPs within miRNA binding sites in the 3&#x02032; UTR can modify miRNA&#x02013;mRNA interactions and substantially affect gene expression [<xref rid="B32-ncrna-11-00032" ref-type="bibr">32</xref>,<xref rid="B33-ncrna-11-00032" ref-type="bibr">33</xref>,<xref rid="B34-ncrna-11-00032" ref-type="bibr">34</xref>].</p><p>SNPs in miRNA binding sites of proto-oncogenes may disrupt their post-transcriptional regulation, leading to overexpression of oncogenic proteins, tumor initiation, progression, and altered drug response in cancer patients [<xref rid="B32-ncrna-11-00032" ref-type="bibr">32</xref>,<xref rid="B35-ncrna-11-00032" ref-type="bibr">35</xref>,<xref rid="B36-ncrna-11-00032" ref-type="bibr">36</xref>,<xref rid="B37-ncrna-11-00032" ref-type="bibr">37</xref>]. Therefore, detecting and characterizing such mutations can improve risk assessment for healthy carriers and enhance the diagnostic and therapeutic toolbox for the patients [<xref rid="B38-ncrna-11-00032" ref-type="bibr">38</xref>].</p><p>The introduction of different bioinformatics tools and software has rendered it feasible to study and analyze SNPs in the 3&#x02032; UTRs. In this study, we used Polymorphism in miRNAs and their corresponding target sites (PolymiRTS) to predict 3&#x02032; UTR SNP-induced changes to the sequences of the miRNA targets. Since the importance of 3&#x02032; UTR SNPs has been highlighted in several studies, their association with various disorders was examined. This study aimed to investigate the effect of 3&#x02032; UTR SNPs in the <italic toggle="yes">STAT1</italic> gene using different bioinformatics methods to determine their oncogenic potential.</p></sec><sec sec-type="results" id="sec2-ncrna-11-00032"><title>2. Results</title><sec id="sec2dot1-ncrna-11-00032"><title>2.1. Retrieval of 3&#x02032; UTR SNPs of STAT1 from NCBI</title><p>We used NCBI to retrieve the 838 SNPs in the 3&#x02032; UTR, and they were used for downstream analysis.</p></sec><sec id="sec2dot2-ncrna-11-00032"><title>2.2. Results of the Impact of 3&#x02032; UTR SNPs on miRNA Binding Sites</title><p>We evaluated the impact of 3&#x02032; UTR SNPs on miRNA binding sites using PolymiRTS, which predicted the association between seventeen 3&#x02032; UTR SNPs and miRNAs, as well as disruption scores, conservation scores, ancestral alleles, modified alleles, context, and score modifications, as shown in <xref rid="app1-ncrna-11-00032" ref-type="app">Table S1</xref>. Twelve 3&#x02032; UTR SNPs created new miRNA-binding sites and their corresponding 30 miRNAs, as shown in <xref rid="ncrna-11-00032-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot3-ncrna-11-00032"><title>2.3. The Effect of 3&#x02032; UTR SNPs on the Secondary Structure of mRNA</title><p>We subjected the wild-type and the twelve 3&#x02032; UTR SNPs that created new miRNA binding sites to RNAfold analysis to evaluate their potential impact on mRNA structure. RNAfold analysis revealed two out of twelve 3&#x02032; UTR SNPs (rs188557905 and rs190542524) showing MFE values rising from &#x02212;35.80 kcal/mol to &#x02212;13.90 kcal/mol and from &#x02212;23.80 kcal/mol to &#x02212;22.30 kcal/mol, respectively. They were predicted to destabilize the mRNA structure. Other SNPs have either minimal or no variation in energy, shown in <xref rid="ncrna-11-00032-t002" ref-type="table">Table 2</xref>.</p></sec><sec id="sec2dot4-ncrna-11-00032"><title>2.4. Cscape Results of Cancer-Associated 3&#x02032; UTR SNPs</title><p>Cscape was used to screen the oncogenic potential of twelve 3&#x02032; UTR SNPs that created new miRNA binding sites. Rs190542524 (T/A) was predicted to be an oncogenic SNP, with the highest score of 0.802671. Meanwhile, rs11305, rs186033487, rs188557905, and rs190542524 (T/G) also had strong predictions for causing cancer, with scores above 0.7. Other SNPs, like rs139958571, rs41363648, rs41481847, rs184180073, rs79073086, and rs139958571, have lower predictions with scores between 0.5 and 0.7. Only one SNP, rs114360225, was predicted as benign, as shown in <xref rid="ncrna-11-00032-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec2dot5-ncrna-11-00032"><title>2.5. Results of miRNet Identification of miRNAs&#x02019; Target Genes</title><p>We submitted the 30 miRNAs that bind to the new miRNA binding sites created by 3&#x02032; UTR SNPs to the miRNet. Only 16 miRNAs (hsa-miR-329-3p, hsa-miR-603, hsa-miR-3941, hsa-miR-4668-5p, hsa-miR-6504-3p, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-6734-3p, hsa-miR-515-5p, hsa-miR-519e-5p, hsa-miR-5088-3p, hsa-miR-136-5p, hsa-miR-5584-5p, hsa-miR-4766-5p, hsa-miR-216b-3p, and hsa-miR-362-3p) had &#x02265;100 interactions and underwent further analysis. MiRNet predicted 2384 genes interacting with the 16 miRNAs, as presented in <xref rid="ncrna-11-00032-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec2dot6-ncrna-11-00032"><title>2.6. Result of Gene Enrichment Analysis</title><p>We used ShinyGo to study the gene enrichment pathways of the miRNAs&#x02019; target genes. We found that 92 genes were significantly enriched in the pathway of cancer (<italic toggle="yes">p</italic>-value 2.04 &#x000d7; 10<sup>&#x02212;5</sup>). Fifty genes in the MAPK signaling pathway (<italic toggle="yes">p</italic>-value 0.0023), forty-one genes in proteoglycans in cancer (<italic toggle="yes">p</italic>-value 0.00025), thirty-seven genes in the microRNAs in cancer pathway (<italic toggle="yes">p</italic>-value 8.97 &#x000d7; 10<sup>&#x02212;5</sup>), and twenty-eight genes were enriched in the FoxO signaling pathway (<italic toggle="yes">p</italic>-value 0.0011), as presented in <xref rid="ncrna-11-00032-f002" ref-type="fig">Figure 2</xref>. The complete enrichment table is presented in <xref rid="app1-ncrna-11-00032" ref-type="app">Table S2</xref>.</p></sec><sec id="sec2dot7-ncrna-11-00032"><title>2.7. Protein&#x02013;Protein Interaction and Disease&#x02013;Gene Association Enrichment</title><p>We submitted the 2384 miRNAs&#x02019; target genes into multiple protein modules of STRING. Protein&#x02013;protein interaction is illustrated in <xref rid="ncrna-11-00032-f003" ref-type="fig">Figure 3</xref>. Next, we used STRING to understand the association between diseases and miRNAs&#x02019; target genes through disease&#x02013;gene association enrichment analysis. The majority of genes involved in pathways of cancer, organ system cancer, gastrointestinal cancer, and hepatobiliary system cancer are shown in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S1</xref>.</p></sec><sec id="sec2dot8-ncrna-11-00032"><title>2.8. Ten miRNAs Enriched in the Pathway of Cancer</title><p>We used miRPathDB to construct a heat map of miRNA enrichment. We found that ten out of the sixteen miRNAs were enriched in the pathways in cancer, namely hsa-miR-3941 (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 2.220), hsa-miR-4668-5p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 2.626), hsa-miR-4287 (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 2.679), hsa-miR-4685-3p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 2.469), hsa-miR-6734-3p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 4.891), hsa-miR-515-5p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 1.375), hsa-miR-519e-5p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 1.302), hsa-miR-5088-3p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 2.303), hsa-miR-136-5p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 1.524), and hsa-miR-5584-5p (&#x02212;log <italic toggle="yes">p</italic>-value &#x0003e; 3.697).</p><p>Moreover, we found 8 out of 16 miRNAs (hsa-miR-603, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-6734-3p, hsa-miR-5088-3p, hsa-miR-136-5p, hsa-miR-5584-5p, and hsa-miR-362-3p) were enriched in the MAPK signaling pathway, 11 miRNAs (hsa-miR-329-3p, hsa-miR-603, hsa-miR-3941, hsa-miR-4668-5p, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-6734-3p, hsa-miR-515-5p, hsa-miR-5088-3p, hsa-miR-5584-5p, and hsa-miR-362-3p) in proteoglycans in cancer, 14 miRNAs (hsa-miR-329-3p, hsa-miR-603, hsa-miR-3941, hsa-miR-4668-5p, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-6734-3p, hsa-miR-515-5p, hsa-miR-519e-5p, hsa-miR-5088-3p, hsa-miR-5584-5p, hsa-miR-4766-5p, hsa-miR-216b-3p, and hsa-miR-362-3p) in microRNAs in cancer, and 12 (hsa-miR-329-3p, hsa-miR-603, hsa-miR-3941, hsa-miR-6504-3p, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-515-5p, hsa-miR-5088-3p, hsa-miR-136-5p, hsa-miR-5584-5p, hsa-miR-216b-3p, and hsa-miR-362-3p) in the FoxO signaling pathway. Complete miRNA enrichment is shown in <xref rid="ncrna-11-00032-f004" ref-type="fig">Figure 4</xref>.</p></sec><sec id="sec2dot9-ncrna-11-00032"><title>2.9. Results of miRNA Differential Expression Analysis in Human Cancer</title><p>We used oncoMIR to predict the significance of miRNA differential expression across cancer types. We found that only five miRNAs (hsa-miR-362-3p, hsa-miR-136-5p, hsa-miR-515-5p, hsa-miR-515-5p, and hsa-miR-329-3p) had significant differential expression in cancer.</p><p>Hsa-miR-362-3p exhibited upregulation in bladder carcinoma (BLCA), breast invasive carcinoma (BRCA), liver hepatocellular carcinoma (LIHC), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC). Moreover, hsa-miR-136-5p showed upregulation in five cancer types: BLCA, BRCA, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and STAD (<italic toggle="yes">p</italic>-value 2.14 &#x000d7; 10<sup>&#x02212;2</sup>). Additionally, hsa-miR-329-3p was upregulated in STAD (<italic toggle="yes">p</italic>-value 4.45 &#x000d7; 10<sup>&#x02212;3</sup>). Furthermore, hsa-miR-515-5p was upregulated in normal lung tissue compared to LUAD, as shown in <xref rid="ncrna-11-00032-t004" ref-type="table">Table 4</xref>.</p><p>We used the StarBase database to visualize the differential expression of four significant differentially expressed miRNAs predicted by oncoMIR (hsa-miR-362-3p, hsa-miR-136-5p, hsa-miR-329-3p, and hsa-miR-515-5p). The results are presented as a box plot in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S2</xref>.</p></sec><sec id="sec2dot10-ncrna-11-00032"><title>2.10. Survival Analysis Study of the Significantly UpRegulated miRNAs in Cancer</title><p>We used the Kaplan&#x02013;Meier plotter to study the survival analysis of the significantly upregulated miRNAs in cancer tissues by both oncoMIR and StarBase. We found that the upregulated group of hsa-miR-362-3p was significantly associated with poor survival in LIHC (Logrank <italic toggle="yes">p</italic> = 0.0046), while the upregulated group of hsa-miR-136-5p was significantly associated with poor survival in BLCA (Logrank <italic toggle="yes">p</italic> = 0.038), LUSC (Logrank <italic toggle="yes">p</italic> = 0.021), and STAD (Logrank <italic toggle="yes">p</italic> = 0.00053), as shown in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S3</xref></p><p>By integration of expression analysis and survival study, we found that hsa-miR-362-3p was significantly upregulated and associated with poor survival in LIHC. Additionally, hsa-miR-136-5p was significantly upregulated and associated with poor survival in BLCA, LUSC, and STAD, as shown in <xref rid="ncrna-11-00032-f005" ref-type="fig">Figure 5</xref>. Next, the interaction between the 3&#x02032; UTR SNP, miRNA, and the target tumor is visualized by the Sankey diagram in <xref rid="ncrna-11-00032-f006" ref-type="fig">Figure 6</xref>.</p></sec></sec><sec id="sec3-ncrna-11-00032"><title>3. Materials and Methods</title><p>The methods of this study are summarized in <xref rid="ncrna-11-00032-f007" ref-type="fig">Figure 7</xref>.</p><sec id="sec3dot1-ncrna-11-00032"><title>3.1. Retrieval of 3&#x02032; UTR SNPs</title><p>We collected data for the human <italic toggle="yes">STAT1</italic> gene from the National Centre for Biotechnology Information (NCBI) website (available at <uri xlink:href="https://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</uri>). We retrieved the 3&#x02032; UTR SNPs from NCBI on 20 December 2024 and analyzed them with the bioinformatics tools.</p></sec><sec id="sec3dot2-ncrna-11-00032"><title>3.2. Evaluation of the Impact of 3&#x02032; UTR SNPs on miRNA Binding Sites</title><p>We evaluated the 3&#x02032; UTR SNPs for their correlation with miRNA binding sites using (PolymiRTS) database (accessible at <uri xlink:href="https://compbio.uthsc.edu/miRSNP/">https://compbio.uthsc.edu/miRSNP/</uri> (accessed on 21 December 2024), which predicts the impact of 3&#x02032; UTR SNPs in miRNA target sites; whether they disrupt a conserved (D), non-conserved (N), or create a new miRNA binding site that could lead to abnormal gene repression (C); or in other cases when the ancestral allele cannot be determined (O). The PolymiRTS database calculates the differences in context + scores between the reference and derived alleles for each 3&#x02032; UTR SNP in the miRNA target sites.</p><p>A difference with a more negative value of the context + score indicates an increased likelihood that the polymorphism significantly altered miRNA targeting of the sequence [<xref rid="B39-ncrna-11-00032" ref-type="bibr">39</xref>]. This study was conducted on 3&#x02032; UTR SNPs that create new miRNA binding sites and were subjected to further analysis.</p></sec><sec id="sec3dot3-ncrna-11-00032"><title>3.3. Determination of the Effect of SNPs on the Secondary Structure of mRNA</title><p>We utilized the RNAfold server from the Vienna RNA package (available at <uri xlink:href="http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi">http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi</uri> (accessed on 22 December 2024)) to examine how 3&#x02032; UTR SNPs that create new miRNA binding sites affect the mRNA&#x02019;s secondary structure [<xref rid="B40-ncrna-11-00032" ref-type="bibr">40</xref>]. The input is the wild-type and SNP sequences that were obtained from NCBI. We obtained the mRNA secondary structures and minimum free energies (MFE) of both the wild-type mRNA and 3&#x02032; UTR SNPs. This package is based on MFE algorithms.</p></sec><sec id="sec3dot4-ncrna-11-00032"><title>3.4. Prediction of Cancer-Associated SNPs</title><p>We used the CScape tools (available at <uri xlink:href="http://cscape.biocompute.org.uk/">http://cscape.biocompute.org.uk/</uri> (accessed on 22 December 2024)) to predict the relationship between 3&#x02032; UTR SNP and cancer development. CScape is a combinatorial tool that predicts if a single mutation in a coding or noncoding part of the genome is oncogenic. The format for the input data was as follows: chromosome, position, reference, and mutant [<xref rid="B41-ncrna-11-00032" ref-type="bibr">41</xref>]. 3&#x02032; UTR SNPs are classified as neutral or oncogenic based on <italic toggle="yes">p</italic>-values ranging from 0 to 1. The tool predicts that a <italic toggle="yes">p</italic>-value &#x0003e;0.5 will be oncogenic, while <italic toggle="yes">p</italic>-value &#x0003c; 0.5 is considered neutral.</p></sec><sec id="sec3dot5-ncrna-11-00032"><title>3.5. Identification of miRNAs&#x02019; Target Genes</title><p>MiRNet (available at <uri xlink:href="https://www.mirnet.ca/">https://www.mirnet.ca/</uri> (accessed on 25 December 2024)) is a web-based platform designed to analyze and visualize miRNA regulatory networks. It integrates various datasets, including miRNA&#x02013;target gene interactions, pathways, and expression profiles, enabling comprehensive analyses of miRNA functions [<xref rid="B42-ncrna-11-00032" ref-type="bibr">42</xref>]. We used the miRNet web interface to retrieve the miRNAs&#x02019; target genes and visualize the miRNA&#x02013;gene interaction network. In this study, we used a degree filter for all miRNA nodes; each miRNA with a degree &#x02265; 100 was included.</p></sec><sec id="sec3dot6-ncrna-11-00032"><title>3.6. Gene Enrichment Analysis</title><p>ShinyGo version (V 0.82) (available at <uri xlink:href="https://bioinformatics.sdstate.edu/go/">https://bioinformatics.sdstate.edu/go/</uri> (accessed on 27 December 2024)) is a graphical web application designed for gene-set enrichment analysis; the input is miRNAs&#x02019; target genes predicted by miRNet. It obtains insights into enriched Gene Ontology (GO) terms and pathways, facilitating the interpretation of biological data [<xref rid="B43-ncrna-11-00032" ref-type="bibr">43</xref>]. We used ShinyGO to analyze miRNAs&#x02019; target genes enrichment and visualize the enriched GO terms and pathways.</p></sec><sec id="sec3dot7-ncrna-11-00032"><title>3.7. Protein&#x02013;Protein Interaction Using the STRING Database</title><p>STRING (available at <uri xlink:href="https://string-db.org/">https://string-db.org/</uri> (accessed on 21 December 2024)) is a biological database that provides a comprehensive resource for known and predicted protein&#x02013;protein interactions. We submitted the miRNAs&#x02019; target genes into multiple protein modules of the STRING database. The threshold for visualizing the protein&#x02013;protein interaction network was set at a medium confidence score of &#x02265;0.4.</p><p>The STRING database integrates various types of associations, including direct physical interactions and indirect functional relationships among proteins [<xref rid="B44-ncrna-11-00032" ref-type="bibr">44</xref>]. STRING also includes tools for functional enrichment analysis, which investigates disease&#x02013;gene associations that are overrepresented in a set of proteins.</p></sec><sec id="sec3dot8-ncrna-11-00032"><title>3.8. MiRNAs Enrichment Analysis</title><p>MiRNA enrichment analysis aims to identify and understand the biological significance of miRNAs. MiRPathDB (available at <uri xlink:href="https://mpd.bioinf.uni-sb.de/">https://mpd.bioinf.uni-sb.de/</uri> (accessed on 28 December 2024)) is a comprehensive database that provides information on miRNAs, their target genes, and their biological pathways [<xref rid="B45-ncrna-11-00032" ref-type="bibr">45</xref>]. The input is miRNA ID; the output is a heat map visualizing miRNA-pathway enrichment, with the &#x02212;log <italic toggle="yes">p</italic>-value representing the significance. The transformation of the <italic toggle="yes">p</italic>-value to &#x02212;log <italic toggle="yes">p</italic>-value is performed to convert the <italic toggle="yes">p</italic>-value into a positive scale, making it easier to visualize and interpret in graphical representations like heat maps.</p></sec><sec id="sec3dot9-ncrna-11-00032"><title>3.9. Pan-Cancer miRNA Differential Expression Analysis</title><p>OncoMIR (<uri xlink:href="https://oncomir.org/oncomir/search_miR_tumor.html">https://oncomir.org/oncomir/search_miR_tumor.html</uri> (accessed on 5 January 2025) is an online resource designed to explore miRNA expression in cancer [<xref rid="B46-ncrna-11-00032" ref-type="bibr">46</xref>]. The input is a full miRNA name to retrieve a list of cancer types where tumor formation is closely associated with the expression of the selected miRNA. Significance is determined by the Student&#x02019;s paired <italic toggle="yes">t</italic>-test, comparing the difference in expression between normal and tumor tissues obtained from patients.</p><p>StarBase (available at <uri xlink:href="https://rnasysu.com/encori/">https://rnasysu.com/encori/</uri> (accessed on 6 January 2025)) is a comprehensive resource for exploring miRNA-target gene interaction maps. It is a biological database that focuses on decoding different RNA interactions, such as those between miRNA and mRNA, miRNA and long noncoding RNA, and protein and noncoding RNA [<xref rid="B47-ncrna-11-00032" ref-type="bibr">47</xref>]. We used this resource to create a box plot to show the differential expression of miRNAs in various cancer types. For a significant result, <italic toggle="yes">p</italic>-value &#x0003c; 0.05.</p></sec><sec id="sec3dot10-ncrna-11-00032"><title>3.10. MiRNAs Survival Analysis</title><p>The Kaplan&#x02013;Meier plotter (available at <uri xlink:href="https://kmplot.com/analysis/">https://kmplot.com/analysis/</uri> (accessed on 8 January 2025)) is a tool used to assess the correlation between gene expression (including mRNA, miRNA, proteins, and DNA) and survival outcomes in large datasets, with over 35,000 samples available for analysis [<xref rid="B48-ncrna-11-00032" ref-type="bibr">48</xref>]. It is commonly utilized in cancer research to identify biomarkers with prognostic significance.</p><p>SR plot (available at <uri xlink:href="https://www.bioinformatics.com.cn/en">https://www.bioinformatics.com.cn/en</uri> (accessed on 12 January 2025)) is a freely accessible, easy-to-use web server that integrates all of the commonly used data visualization and graphing functions [<xref rid="B49-ncrna-11-00032" ref-type="bibr">49</xref>]. We used the SR plot to create a Sankey diagram, which is used to visualize the relation between miRNAs, associated 3&#x02032; UTR SNPs, and cancer.</p></sec></sec><sec sec-type="discussion" id="sec4-ncrna-11-00032"><title>4. Discussion</title><p>In the current study, a total of 838 SNPs in the 3&#x02032; UTR were retrieved from NCBI.</p><p>We used the PolymiRTS tool to study the effect of the 3&#x02032; UTR SNPs on the miRNA binding sites. Twelve 3&#x02032; UTR SNPs were predicted to create thirty new miRNA binding sites (<xref rid="ncrna-11-00032-t001" ref-type="table">Table 1</xref>). These SNPs were Rs11305, rs184180073, rs41363648, rs188557905, rs186033487, rs79073086, rs114360225, rs139958571, rs182394503, rs190542524, rs182725919, and rs41481847. Next, we used the RNAfold server to predict how the twelve 3&#x02032; UTR SNPs would affect the secondary structure of the mRNA. Only two 3&#x02032; UTR SNPs (rs188557905 and rs190542524) were predicted to destabilize the secondary structure of mRNAs, which may result in lower levels of mRNA (<xref rid="ncrna-11-00032-t002" ref-type="table">Table 2</xref>). Previous studies correlated with the findings that 3&#x02032; UTR SNPs have a destabilizing effect on the mRNA with many diseases [<xref rid="B50-ncrna-11-00032" ref-type="bibr">50</xref>,<xref rid="B51-ncrna-11-00032" ref-type="bibr">51</xref>]. A study comparing two groups found that a specific 3&#x02032; UTR SNP, rs929271, on the leukemia inhibitory factor (LIF) destabilized the secondary structure of mRNA. In a different study, the rs2229611 SNP in the G6PC1 gene was found to decrease the stability of mRNA using RNAfold, which was linked to a more severe disease phenotype in GSD-Ia patients [<xref rid="B52-ncrna-11-00032" ref-type="bibr">52</xref>]</p><p>To examine how 3&#x02032; UTR SNPs might cause cancer, we used the Cscape tool and found eleven out of the twelve 3&#x02032; UTR SNPs were predicted to be oncogenic (score &#x0003e; 0.5), with rs190542524 (T/A) having the highest confidence oncogenic prediction (score 0.802671). One SNP, rs114360225, was predicted as benign, with a low-confidence neutral prediction (score 0.468060), as shown in <xref rid="ncrna-11-00032-t003" ref-type="table">Table 3</xref>.</p><p>ClinVar classifies all 3&#x02032; UTR SNPs predicted as oncogenic in Cscape as benign, except rs186033487 and rs188557905, which have classification of uncertain significance.</p><p>Next, we used miRNet to find the miRNAs&#x02019; target genes (<xref rid="ncrna-11-00032-f001" ref-type="fig">Figure 1</xref>). Next, we utilized ShinyGO and miRPathDB to conduct gene and miRNA enrichment analyses to elucidate the pathways associated with miRNAs&#x02019; target genes and miRNAs, respectively.</p><p>We found that both miRNAs&#x02019; target genes and miRNAs were significantly enriched in the same pathways involved in tumorigenesis, angiogenesis, and cell proliferation; the pathways were pathways in cancer, the MAPK signaling pathway, proteoglycans in cancer, microRNAs in the cancer pathway, and the FoxO signaling pathway (<xref rid="ncrna-11-00032-f002" ref-type="fig">Figure 2</xref>). We found that 92 miRNA target genes were significantly enriched in the pathways in cancer (<italic toggle="yes">p</italic>-value 2.04 &#x000d7; 10<sup>&#x02212;5</sup>), and 50 genes were enriched in the MAPK signaling pathway (<italic toggle="yes">p</italic>-value 0.0023). Research has shown that the MAPK pathway influences cell proliferation, survival, and differentiation and thus plays a critical role in cancer biology [<xref rid="B53-ncrna-11-00032" ref-type="bibr">53</xref>]. The gene enrichment analysis revealed that 41 genes were enriched in proteoglycans in cancer (<italic toggle="yes">p</italic>-value 0.00025) and 37 genes in the microRNAs in the cancer pathway (<italic toggle="yes">p</italic>-value 8.97 &#x000d7; 10<sup>&#x02212;5</sup>). Additionally, 28 genes were enriched in the FoxO signaling pathway (<italic toggle="yes">p</italic>-value 0.0011), which is involved in transcription factors that regulate various cellular processes such as apoptosis, cell cycle control, and metabolism and is frequently implicated in cancer biology (<xref rid="app1-ncrna-11-00032" ref-type="app">Table S2</xref>).</p><p>Moreover, MiRNAs play a crucial and multifaceted role in cancer pathways. They act as both oncogenes and tumor suppressor genes [<xref rid="B54-ncrna-11-00032" ref-type="bibr">54</xref>]. They can also influence cellular processes such as cell cycle regulation, apoptosis, angiogenesis, and metastasis [<xref rid="B55-ncrna-11-00032" ref-type="bibr">55</xref>,<xref rid="B56-ncrna-11-00032" ref-type="bibr">56</xref>]</p><p>Our miRNA enrichment result showed 10 out of 16 miRNAs were enriched in the pathways in cancer, namely hsa-miR-3941, hsa-miR-4668-5p, hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-6734-3p, hsa-miR-515-5p, hsa-miR-519e-5p, hsa-miR-5088-3p, hsa-miR-136-5p, and hsa-miR-5584-5p. Moreover, we found 8 out of 16 miRNAs were enriched in the MAPK signaling pathway, 11 in proteoglycans in cancer, 14 in microRNAs in cancer, and 12 in the FoxO signaling pathway (<xref rid="ncrna-11-00032-f004" ref-type="fig">Figure 4</xref>).</p><p>Differential expression analysis of miRNAs in cancer from the oncoMIR and StarBase databases showed that hsa-miR-362-3p was upregulated in BLCA, BRCA, LIHC, STAD, and UCEC; hsa-miR-136-5p was upregulated in BLCA, LUAD, LUSC, and STAD; the StarBase database predicted hsa-miR-136-5p to be insignificantly upregulated in BRCA (<italic toggle="yes">p</italic>-value 0.82), while oncoMIR predicted it as significantly upregulated (<italic toggle="yes">p</italic>-value 6.39 &#x000d7; 10<sup>&#x02212;4</sup>), and hsa-miR-329-3p was upregulated in STAD. Both oncoMIR and StarBase databases predicted hsa-miR-515-5p as significantly downregulated in LUAD, with <italic toggle="yes">p</italic>-values of 4.89 &#x000d7; 10<sup>&#x02212;2</sup> and 0.0003, respectively).</p><p>Upon reviewing the literature, we found that only hsa-miR-515-5p has some relevance in the context of the STAT1 gene, particularly in thyroid cancer, where miR-515-5p was downregulated [<xref rid="B57-ncrna-11-00032" ref-type="bibr">57</xref>]. However, a direct association between hsa-miR-515-5p and STAT1 is not explicitly detailed in the literature, suggesting further exploration may be needed.</p><p>Hypothetically, oncogenic miRNAs should be upregulated in the tumor tissue and associated with poor survival. We integrated the results of expression analysis by the StarBase database and survival analysis by the Kaplan&#x02013;Meier Plotter. We found that hsa-miR-362-3p was significantly upregulated and linked to poor survival in LIHC. On the other hand, hsa-miR-136-5p was significantly upregulated and linked to poor survival in BLCA, LUSC, and STAD (<xref rid="ncrna-11-00032-f005" ref-type="fig">Figure 5</xref>). As a result, both hsa-miR-362-3p and hsa-miR-136-5p may have a potential oncogenic role in cancer. They were predicted to recognize new miRNA binding sites created by rs114360225 (predicted as a benign SNP by Cscape) and rs190542524 (predicted as an oncogenic SNP by Cscape), respectively.</p><p>The effect of rs114360225 and rs190542524 on cancer is not directly addressed in the literature. However, both genetic variants can influence cancer susceptibility and progression by regulating gene expression and signaling pathways. Alteration of the STAT1 expression can affect the cellular response to stress and inflammation, potentially influencing cancer development. Both 3&#x02032; UTR SNPs may interfere with STAT1 regulation by creating new miRNA binding sites that downregulate its expression, potentially impairing its tumor suppressor effect. While STAT1 protein is involved in various signaling pathways that regulate cell growth and apoptosis. Genetic variants may affect these pathways and result in an increase in cancer cell proliferation or resistance to apoptosis.</p><p>In agreement with our result, which is presented in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S2Q</xref>, the expression of hsa-miR-136-5p was studied in a cohort of 1242 samples provided by the Gene Expression Omnibus and the Cancer Genome Atlas. They found that hsa-miR-136-5p is upregulated in LUAD versus normal tissues and involved in the molecular mechanism of LUAD through inhibiting the expressions of downstream genes involved in cell adhesion (claudin-18, sialophorin, and syndecan 2) [<xref rid="B58-ncrna-11-00032" ref-type="bibr">58</xref>]. However, we found that its upregulation is non-significantly associated with poor survival (<italic toggle="yes">p</italic>-value 0.07), as shown in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S3G</xref>. As part of a different study, a genome-wide miRNA microarray was used to find miRNAs that were differentially expressed in hepatocellular carcinoma on cirrhotic livers. They found hsa-miR-136 was downregulated [<xref rid="B59-ncrna-11-00032" ref-type="bibr">59</xref>]. This result is in agreement with ours: hsa-miR-136 is significantly downregulated in LIHC (<italic toggle="yes">p</italic>-value 2.1 &#x000d7; 10<sup>&#x02212;5</sup>), as presented in <xref rid="app1-ncrna-11-00032" ref-type="app">Figure S2P</xref>. Several types of cancer have been linked hsa-miR-362-3p. Studies indicate its association with breast [<xref rid="B60-ncrna-11-00032" ref-type="bibr">60</xref>,<xref rid="B61-ncrna-11-00032" ref-type="bibr">61</xref>], colorectal [<xref rid="B62-ncrna-11-00032" ref-type="bibr">62</xref>], cervical [<xref rid="B63-ncrna-11-00032" ref-type="bibr">63</xref>,<xref rid="B64-ncrna-11-00032" ref-type="bibr">64</xref>], and ovarian cancer [<xref rid="B61-ncrna-11-00032" ref-type="bibr">61</xref>,<xref rid="B65-ncrna-11-00032" ref-type="bibr">65</xref>,<xref rid="B66-ncrna-11-00032" ref-type="bibr">66</xref>,<xref rid="B67-ncrna-11-00032" ref-type="bibr">67</xref>], suggesting it may influence cancer progression and patient prognosis.</p><p>To our knowledge, there is no published study correlating hsa-miR-136-5p to BLCA, LUSC, or STAD. Additionally, there is no published information discussing the expression of hsa-miR-362-3p in LIHC.</p></sec><sec sec-type="conclusions" id="sec5-ncrna-11-00032"><title>5. Conclusions</title><p>We concluded that the oncogenic 3&#x02032; UTR SNP rs190542524 was predicted to create a new binding site for the oncogenic miRNA hsa-miR-136-5p, which is significantly upregulated in BLCA, LUSC, and STAD and associated with poor survival. Additionally, rs114360225 was predicted to create a new binding site for hsa-miR-362-3p, influencing LIHC and associated with poor survival (<xref rid="ncrna-11-00032-f006" ref-type="fig">Figure 6</xref>).</p><p>However, there are some limitations to the current study, such as the bioinformatics analysis performed on 3&#x02032; UTR variants of STAT1 not being disease-specific. The functional significance of the UTR variants determined via bioinformatics analysis requires experimental validation. Future functional studies could provide insights into the role of STAT1 in cancer biology by investigating how rs190542524 and rs114360225 affect its function at the molecular level. Understanding the impact of the 3&#x02032; UTR SNPs on cancer could lead to personalized treatment strategies, particularly in tailoring immunotherapies that leverage the immune system&#x02019;s response to tumors.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ncrna-11-00032"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/ncrna11030032/s1">https://www.mdpi.com/article/10.3390/ncrna11030032/s1</uri>. Table S1: PolymiRTS analysis showing chromosomal location, ancestral alleles, allele, miRNA ID, conservation score, miRNA binding site and functional classification of the SNPs in the 3&#x02032; UTR of STAT1 gene; Table S2: miRNA target genes enrichment analysis by ShinyGo; Figure S1: Disease-gene association enrichments miRNAs&#x02019; target genes using STRING database; Figure S2: The expression analysis of the four significant differentially expressed miRNAs (hsa-miR-362-3p (A&#x02013;J), hsa-miR-136-5p (K&#x02013;T), hsa-miR-329-3p (T&#x02013;W)) and hsa-miR-515-5p (X), in human cancer using StarBase database; Figure S3: Survival analysis of the significantly up-regulated miRNAs in cancer (hsa-miR-362 (A&#x02013;D), hsa-miR-136 (E&#x02013;I), using Kaplan Meier Plotter.</p><supplementary-material id="ncrna-11-00032-s001" position="float" content-type="local-data"><media xlink:href="ncrna-11-00032-s001.zip"/></supplementary-material></app></app-group><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article/<xref rid="app1-ncrna-11-00032" ref-type="app">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author declares no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ncrna-11-00032"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gongora</surname><given-names>C.</given-names></name>
<name><surname>Mechti</surname><given-names>N.</given-names></name>
</person-group><article-title>Interferon signaling pathways</article-title><source>Bull. Cancer</source><year>1999</year><volume>86</volume><fpage>911</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">10586107</pub-id>
</element-citation></ref><ref id="B2-ncrna-11-00032"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horvath</surname><given-names>C.M.</given-names></name>
</person-group><article-title>The Jak-STAT pathway stimulated by interferon gamma</article-title><source>Sci. STKE</source><year>2004</year><volume>2004</volume><fpage>tr8</fpage><pub-id pub-id-type="doi">10.1126/stke.2602004tr8</pub-id><pub-id pub-id-type="pmid">15561980</pub-id>
</element-citation></ref><ref id="B3-ncrna-11-00032"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abroun</surname><given-names>S.</given-names></name>
<name><surname>Saki</surname><given-names>N.</given-names></name>
<name><surname>Ahmadvand</surname><given-names>M.</given-names></name>
<name><surname>Asghari</surname><given-names>F.</given-names></name>
<name><surname>Salari</surname><given-names>F.</given-names></name>
<name><surname>Rahim</surname><given-names>F.</given-names></name>
</person-group><article-title>Stats: An old story, yet mesmerizing</article-title><source>Cell J.</source><year>2015</year><volume>17</volume><fpage>395</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.22074/cellj.2015.1</pub-id><pub-id pub-id-type="pmid">26464811</pub-id>
</element-citation></ref><ref id="B4-ncrna-11-00032"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benekli</surname><given-names>M.</given-names></name>
<name><surname>Baer</surname><given-names>M.R.</given-names></name>
<name><surname>Baumann</surname><given-names>H.</given-names></name>
<name><surname>Wetzler</surname><given-names>M.</given-names></name>
</person-group><article-title>Signal transducer and activator of transcription proteins in leukemias</article-title><source>Blood</source><year>2003</year><volume>101</volume><fpage>2940</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-04-1204</pub-id><pub-id pub-id-type="pmid">12480704</pub-id>
</element-citation></ref><ref id="B5-ncrna-11-00032"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shuai</surname><given-names>K.</given-names></name>
</person-group><article-title>Modulation of STAT signaling by STAT-interacting proteins</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>2638</fpage><lpage>2644</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203522</pub-id><pub-id pub-id-type="pmid">10851063</pub-id>
</element-citation></ref><ref id="B6-ncrna-11-00032"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stark</surname><given-names>G.R.</given-names></name>
<name><surname>Darnell</surname><given-names>J.E.</given-names></name>
</person-group><article-title>The JAK-STAT pathway at twenty</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>503</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.013</pub-id><pub-id pub-id-type="pmid">22520844</pub-id>
</element-citation></ref><ref id="B7-ncrna-11-00032"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamal</surname><given-names>E.</given-names></name>
<name><surname>Kaddam</surname><given-names>L.A.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
<name><surname>Alabdulkarim</surname><given-names>A.</given-names></name>
</person-group><article-title>Integrating artificial intelligence and bioinformatics methods to identify disruptive STAT1 variants impacting protein stability and function</article-title><source>Genes</source><year>2025</year><volume>16</volume><elocation-id>303</elocation-id><pub-id pub-id-type="doi">10.3390/genes16030303</pub-id><pub-id pub-id-type="pmid">40149454</pub-id>
</element-citation></ref><ref id="B8-ncrna-11-00032"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.-C.</given-names></name>
<name><surname>Md Yusof</surname><given-names>H.H.</given-names></name>
<name><surname>Leong</surname><given-names>M.P.-Y.</given-names></name>
<name><surname>Zainal Abidin</surname><given-names>S.</given-names></name>
<name><surname>Seth</surname><given-names>E.A.</given-names></name>
<name><surname>Hewitt</surname><given-names>C.A.</given-names></name>
<name><surname>Vidyadaran</surname><given-names>S.</given-names></name>
<name><surname>Nordin</surname><given-names>N.</given-names></name>
<name><surname>Scott</surname><given-names>H.S.</given-names></name>
<name><surname>Cheah</surname><given-names>P.-S.</given-names></name>
<etal/>
</person-group><article-title>Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model</article-title><source>Int. J. Neurosci.</source><year>2019</year><volume>129</volume><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1080/00207454.2019.1580280</pub-id><pub-id pub-id-type="pmid">30775947</pub-id>
</element-citation></ref><ref id="B9-ncrna-11-00032"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heim</surname><given-names>M.H.</given-names></name>
</person-group><article-title>The Jak-STAT pathway: Cytokine signalling from the receptor to the nucleus</article-title><source>J. Recept. Signal Transduct. Res.</source><year>1999</year><volume>19</volume><fpage>75</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.3109/10799899909036638</pub-id><pub-id pub-id-type="pmid">10071751</pub-id>
</element-citation></ref><ref id="B10-ncrna-11-00032"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ga&#x00142;ecka</surname><given-names>M.</given-names></name>
<name><surname>Szemraj</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>K.-P.</given-names></name>
<name><surname>Halaris</surname><given-names>A.</given-names></name>
<name><surname>Maes</surname><given-names>M.</given-names></name>
<name><surname>Skiba</surname><given-names>A.</given-names></name>
<name><surname>Ga&#x00142;ecki</surname><given-names>P.</given-names></name>
<name><surname>Bli&#x0017a;niewska-Kowalska</surname><given-names>K.</given-names></name>
</person-group><article-title>Is the JAK-STAT Signaling Pathway Involved in the Pathogenesis of Depression?</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>2056</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11072056</pub-id><pub-id pub-id-type="pmid">35407663</pub-id>
</element-citation></ref><ref id="B11-ncrna-11-00032"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
</person-group><article-title>STAT1 in cancer: Friend or foe?</article-title><source>Discov. Med.</source><year>2017</year><volume>24</volume><fpage>19</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">28950072</pub-id>
</element-citation></ref><ref id="B12-ncrna-11-00032"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koromilas</surname><given-names>A.E.</given-names></name>
<name><surname>Sexl</surname><given-names>V.</given-names></name>
</person-group><article-title>The tumor suppressor function of STAT1 in breast cancer</article-title><source>JAK-STAT</source><year>2013</year><volume>2</volume><fpage>e23353</fpage><pub-id pub-id-type="doi">10.4161/jkst.23353</pub-id><pub-id pub-id-type="pmid">24058806</pub-id>
</element-citation></ref><ref id="B13-ncrna-11-00032"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crn&#x0010d;ec</surname><given-names>I.</given-names></name>
<name><surname>Modak</surname><given-names>M.</given-names></name>
<name><surname>Gordziel</surname><given-names>C.</given-names></name>
<name><surname>Svinka</surname><given-names>J.</given-names></name>
<name><surname>Scharf</surname><given-names>I.</given-names></name>
<name><surname>Moritsch</surname><given-names>S.</given-names></name>
<name><surname>Pathria</surname><given-names>P.</given-names></name>
<name><surname>Schlederer</surname><given-names>M.</given-names></name>
<name><surname>Kenner</surname><given-names>L.</given-names></name>
<name><surname>Timelthaler</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>STAT1 is a sex-specific tumor suppressor in colitis-associated colorectal cancer</article-title><source>Mol. Oncol.</source><year>2018</year><volume>12</volume><fpage>514</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.12178</pub-id><pub-id pub-id-type="pmid">29419930</pub-id>
</element-citation></ref><ref id="B14-ncrna-11-00032"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Molavi</surname><given-names>O.</given-names></name>
<name><surname>Su</surname><given-names>M.</given-names></name>
<name><surname>Lai</surname><given-names>R.</given-names></name>
</person-group><article-title>The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><elocation-id>791</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-14-791</pub-id><pub-id pub-id-type="pmid">25355139</pub-id>
</element-citation></ref><ref id="B15-ncrna-11-00032"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kovacic</surname><given-names>B.</given-names></name>
<name><surname>Stoiber</surname><given-names>D.</given-names></name>
<name><surname>Moriggl</surname><given-names>R.</given-names></name>
<name><surname>Weisz</surname><given-names>E.</given-names></name>
<name><surname>Ott</surname><given-names>R.G.</given-names></name>
<name><surname>Kreibich</surname><given-names>R.</given-names></name>
<name><surname>Levy</surname><given-names>D.E.</given-names></name>
<name><surname>Beug</surname><given-names>H.</given-names></name>
<name><surname>Freissmuth</surname><given-names>M.</given-names></name>
<name><surname>Sexl</surname><given-names>V.</given-names></name>
</person-group><article-title>STAT1 acts as a tumor promoter for leukemia development</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.05.025</pub-id><pub-id pub-id-type="pmid">16843267</pub-id>
</element-citation></ref><ref id="B16-ncrna-11-00032"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zellmer</surname><given-names>V.R.</given-names></name>
<name><surname>Schnepp</surname><given-names>P.M.</given-names></name>
<name><surname>Fracci</surname><given-names>S.L.</given-names></name>
<name><surname>Tan</surname><given-names>X.</given-names></name>
<name><surname>Howe</surname><given-names>E.N.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
</person-group><article-title>Tumor-induced Stromal STAT1 Accelerates Breast Cancer via Deregulating Tissue Homeostasis</article-title><source>Mol. Cancer Res.</source><year>2017</year><volume>15</volume><fpage>585</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-16-0312</pub-id><pub-id pub-id-type="pmid">28108623</pub-id>
</element-citation></ref><ref id="B17-ncrna-11-00032"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>G.</given-names></name>
</person-group><article-title>The dual role of STAT1 in ovarian cancer: Insight into molecular mechanisms and application potentials</article-title><source>Front. Cell Dev. Biol.</source><year>2021</year><volume>9</volume><elocation-id>636595</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.636595</pub-id><pub-id pub-id-type="pmid">33834023</pub-id>
</element-citation></ref><ref id="B18-ncrna-11-00032"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russo</surname><given-names>F.</given-names></name>
<name><surname>Fiscon</surname><given-names>G.</given-names></name>
<name><surname>Conte</surname><given-names>F.</given-names></name>
<name><surname>Rizzo</surname><given-names>M.</given-names></name>
<name><surname>Paci</surname><given-names>P.</given-names></name>
<name><surname>Pellegrini</surname><given-names>M.</given-names></name>
</person-group><article-title>Interplay between long noncoding rnas and micrornas in cancer</article-title><source>Methods Mol. Biol.</source><year>2018</year><volume>1819</volume><fpage>75</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-8618-7_4</pub-id><pub-id pub-id-type="pmid">30421400</pub-id>
</element-citation></ref><ref id="B19-ncrna-11-00032"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>J.</given-names></name>
<name><surname>Yi</surname><given-names>C.</given-names></name>
</person-group><article-title>The epitranscriptome of small non-coding RNAs</article-title><source>Noncoding RNA Res.</source><year>2021</year><volume>6</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.ncrna.2021.10.002</pub-id><pub-id pub-id-type="pmid">34820590</pub-id>
</element-citation></ref><ref id="B20-ncrna-11-00032"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grosshans</surname><given-names>H.</given-names></name>
<name><surname>Slack</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Micro-RNAs: Small is plentiful</article-title><source>J. Cell Biol.</source><year>2002</year><volume>156</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1083/jcb.200111033</pub-id><pub-id pub-id-type="pmid">11781331</pub-id>
</element-citation></ref><ref id="B21-ncrna-11-00032"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stefani</surname><given-names>G.</given-names></name>
<name><surname>Slack</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Small non-coding RNAs in animal development</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2008</year><volume>9</volume><fpage>219</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/nrm2347</pub-id><pub-id pub-id-type="pmid">18270516</pub-id>
</element-citation></ref><ref id="B22-ncrna-11-00032"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anglicheau</surname><given-names>D.</given-names></name>
<name><surname>Muthukumar</surname><given-names>T.</given-names></name>
<name><surname>Suthanthiran</surname><given-names>M.</given-names></name>
</person-group><article-title>MicroRNAs: Small RNAs with big effects</article-title><source>Transplantation</source><year>2010</year><volume>90</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1097/TP.0b013e3181e913c2</pub-id><pub-id pub-id-type="pmid">20574417</pub-id>
</element-citation></ref><ref id="B23-ncrna-11-00032"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>Z.</given-names></name>
<name><surname>Rajewsky</surname><given-names>N.</given-names></name>
</person-group><article-title>The impact of miRNA target sites in coding sequences and in 3&#x02032;UTRs</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e18067</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0018067</pub-id><pub-id pub-id-type="pmid">21445367</pub-id>
</element-citation></ref><ref id="B24-ncrna-11-00032"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>V&#x000e5;ge</surname><given-names>J.</given-names></name>
<name><surname>Lingaas</surname><given-names>F.</given-names></name>
</person-group><article-title>Single nucleotide polymorphisms (SNPs) in coding regions of canine dopamine- and serotonin-related genes</article-title><source>BMC Genet.</source><year>2008</year><volume>9</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2156-9-10</pub-id><pub-id pub-id-type="pmid">18226236</pub-id>
</element-citation></ref><ref id="B25-ncrna-11-00032"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tak</surname><given-names>Y.G.</given-names></name>
<name><surname>Farnham</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Making sense of GWAS: Using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome</article-title><source>Epigenetics Chromatin</source><year>2015</year><volume>8</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s13072-015-0050-4</pub-id><pub-id pub-id-type="pmid">26719772</pub-id>
</element-citation></ref><ref id="B26-ncrna-11-00032"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ryczek</surname><given-names>N.</given-names></name>
<name><surname>&#x00141;y&#x0015b;</surname><given-names>A.</given-names></name>
<name><surname>Maka&#x00142;owska</surname><given-names>I.</given-names></name>
</person-group><article-title>The Functional Meaning of 5&#x02032;UTR in Protein-Coding Genes</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>2976</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24032976</pub-id><pub-id pub-id-type="pmid">36769304</pub-id>
</element-citation></ref><ref id="B27-ncrna-11-00032"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>M.</given-names></name>
<name><surname>Jiao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>5&#x02032;-UTR SNP of FGF13 causes translational defect and intellectual disability</article-title><source>eLife</source><year>2021</year><volume>10</volume><fpage>e63021</fpage><pub-id pub-id-type="doi">10.7554/eLife.63021</pub-id><pub-id pub-id-type="pmid">34184986</pub-id>
</element-citation></ref><ref id="B28-ncrna-11-00032"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soukarieh</surname><given-names>O.</given-names></name>
<name><surname>Meguerditchian</surname><given-names>C.</given-names></name>
<name><surname>Proust</surname><given-names>C.</given-names></name>
<name><surname>A&#x000ef;ssi</surname><given-names>D.</given-names></name>
<name><surname>Eyries</surname><given-names>M.</given-names></name>
<name><surname>Goyenvalle</surname><given-names>A.</given-names></name>
<name><surname>Tr&#x000e9;gou&#x000eb;t</surname><given-names>D.-A.</given-names></name>
</person-group><article-title>Common and rare 5&#x02032;UTR variants altering upstream open reading frames in cardiovascular genomics</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>9</volume><elocation-id>841032</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2022.841032</pub-id><pub-id pub-id-type="pmid">35387445</pub-id>
</element-citation></ref><ref id="B29-ncrna-11-00032"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-Z.</given-names></name>
<name><surname>Sun</surname><given-names>Q.-W.</given-names></name>
<name><surname>Zhao</surname><given-names>X.-Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Li</surname><given-names>F.-F.</given-names></name>
<name><surname>Liu</surname><given-names>S.-L.</given-names></name>
</person-group><article-title>Associations of CXCL1 gene 5&#x02032;UTR variations with ovarian cancer</article-title><source>J. Ovarian Res.</source><year>2020</year><volume>13</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s13048-020-00640-9</pub-id><pub-id pub-id-type="pmid">32326946</pub-id>
</element-citation></ref><ref id="B30-ncrna-11-00032"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>Y.</given-names></name>
<name><surname>Arora</surname><given-names>S.</given-names></name>
<name><surname>Schuster</surname><given-names>S.L.</given-names></name>
<name><surname>Corey</surname><given-names>L.</given-names></name>
<name><surname>Fitzgibbon</surname><given-names>M.</given-names></name>
<name><surname>Wladyka</surname><given-names>C.L.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Coleman</surname><given-names>I.M.</given-names></name>
<name><surname>Delrow</surname><given-names>J.J.</given-names></name>
<name><surname>Corey</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Multiplexed functional genomic analysis of 5&#x02032; untranslated region mutations across the spectrum of prostate cancer</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>4217</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24445-6</pub-id><pub-id pub-id-type="pmid">34244513</pub-id>
</element-citation></ref><ref id="B31-ncrna-11-00032"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mendell</surname><given-names>J.T.</given-names></name>
<name><surname>Dietz</surname><given-names>H.C.</given-names></name>
</person-group><article-title>When the message goes awry: Disease-producing mutations that influence mRNA content and performance</article-title><source>Cell</source><year>2001</year><volume>107</volume><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00583-9</pub-id><pub-id pub-id-type="pmid">11719181</pub-id>
</element-citation></ref><ref id="B32-ncrna-11-00032"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>C.-Q.</given-names></name>
<name><surname>Zhang</surname><given-names>J.-H.</given-names></name>
<name><surname>Shi</surname><given-names>J.-C.</given-names></name>
<name><surname>Cao</surname><given-names>X.-Q.</given-names></name>
<name><surname>Song</surname><given-names>C.-H.</given-names></name>
<name><surname>Hassan</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Dai</surname><given-names>L.-P.</given-names></name>
<name><surname>Zhang</surname><given-names>J.-Y.</given-names></name>
<name><surname>Wang</surname><given-names>K.-J.</given-names></name>
</person-group><article-title>Bioinformatic Prediction of SNPs within miRNA Binding Sites of Inflammatory Genes Associated with Gastric Cancer</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2014</year><volume>15</volume><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2014.15.2.937</pub-id><pub-id pub-id-type="pmid">24568522</pub-id>
</element-citation></ref><ref id="B33-ncrna-11-00032"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ergun</surname><given-names>S.</given-names></name>
<name><surname>Oztuzcu</surname><given-names>S.</given-names></name>
</person-group><article-title>Sequence-based analysis of 5&#x02032;UTR and coding regions of CASP3 in terms of miRSNPs and SNPs in targetting miRNAs</article-title><source>Comput. Biol. Chem.</source><year>2016</year><volume>62</volume><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2016.04.003</pub-id><pub-id pub-id-type="pmid">27107179</pub-id>
</element-citation></ref><ref id="B34-ncrna-11-00032"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>J.</given-names></name>
<name><surname>Tong</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.-M.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Hu</surname><given-names>T.</given-names></name>
<name><surname>Shan</surname><given-names>G.</given-names></name>
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>A.-Y.</given-names></name>
</person-group><article-title>Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis</article-title><source>Hum. Mutat.</source><year>2012</year><volume>33</volume><fpage>254</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1002/humu.21641</pub-id><pub-id pub-id-type="pmid">22045659</pub-id>
</element-citation></ref><ref id="B35-ncrna-11-00032"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manikandan</surname><given-names>M.</given-names></name>
<name><surname>Munirajan</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Single nucleotide polymorphisms in microRNA binding sites of oncogenes: Implications in cancer and pharmacogenomics</article-title><source>OMICS</source><year>2014</year><volume>18</volume><fpage>142</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1089/omi.2013.0098</pub-id><pub-id pub-id-type="pmid">24286505</pub-id>
</element-citation></ref><ref id="B36-ncrna-11-00032"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ergun</surname><given-names>S.</given-names></name>
<name><surname>Oztuzcu</surname><given-names>S.</given-names></name>
</person-group><article-title>Computational analysis of 3&#x02032;UTR region of CASP3 with respect to miRSNPs and SNPs in targetting miRNAs</article-title><source>Comput. Biol. Chem.</source><year>2014</year><volume>53PB</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.compbiolchem.2014.10.004</pub-id><pub-id pub-id-type="pmid">25462332</pub-id>
</element-citation></ref><ref id="B37-ncrna-11-00032"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Preskill</surname><given-names>C.</given-names></name>
<name><surname>Weidhaas</surname><given-names>J.B.</given-names></name>
</person-group><article-title>SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers</article-title><source>Crit. Rev. Oncog.</source><year>2013</year><volume>18</volume><fpage>327</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.2013007254</pub-id><pub-id pub-id-type="pmid">23614619</pub-id>
</element-citation></ref><ref id="B38-ncrna-11-00032"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lange</surname><given-names>M.</given-names></name>
<name><surname>Begolli</surname><given-names>R.</given-names></name>
<name><surname>Giakountis</surname><given-names>A.</given-names></name>
</person-group><article-title>Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine</article-title><source>Noncoding RNA</source><year>2021</year><volume>7</volume><elocation-id>47</elocation-id><pub-id pub-id-type="doi">10.3390/ncrna7030047</pub-id><pub-id pub-id-type="pmid">34449663</pub-id>
</element-citation></ref><ref id="B39-ncrna-11-00032"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattacharya</surname><given-names>A.</given-names></name>
<name><surname>Ziebarth</surname><given-names>J.D.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
</person-group><article-title>PolymiRTS Database 3.0: Linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>D86</fpage><lpage>D91</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1028</pub-id><pub-id pub-id-type="pmid">24163105</pub-id>
</element-citation></ref><ref id="B40-ncrna-11-00032"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gruber</surname><given-names>A.R.</given-names></name>
<name><surname>Bernhart</surname><given-names>S.H.</given-names></name>
<name><surname>Lorenz</surname><given-names>R.</given-names></name>
</person-group><article-title>The ViennaRNA web services</article-title><source>Methods Mol. Biol.</source><year>2015</year><volume>1269</volume><fpage>307</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-2291-8_19</pub-id><pub-id pub-id-type="pmid">25577387</pub-id>
</element-citation></ref><ref id="B41-ncrna-11-00032"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rogers</surname><given-names>M.F.</given-names></name>
<name><surname>Shihab</surname><given-names>H.A.</given-names></name>
<name><surname>Gaunt</surname><given-names>T.R.</given-names></name>
<name><surname>Campbell</surname><given-names>C.</given-names></name>
</person-group><article-title>CScape: A tool for predicting oncogenic single-point mutations in the cancer genome</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>11597</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-11746-4</pub-id><pub-id pub-id-type="pmid">28912487</pub-id>
</element-citation></ref><ref id="B42-ncrna-11-00032"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>L.</given-names></name>
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Soufan</surname><given-names>O.</given-names></name>
<name><surname>Xia</surname><given-names>J.</given-names></name>
</person-group><article-title>miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>W244</fpage><lpage>W251</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa467</pub-id><pub-id pub-id-type="pmid">32484539</pub-id>
</element-citation></ref><ref id="B43-ncrna-11-00032"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ge</surname><given-names>S.X.</given-names></name>
<name><surname>Jung</surname><given-names>D.</given-names></name>
<name><surname>Yao</surname><given-names>R.</given-names></name>
</person-group><article-title>ShinyGO: A graphical gene-set enrichment tool for animals and plants</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><fpage>2628</fpage><lpage>2629</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz931</pub-id><pub-id pub-id-type="pmid">31882993</pub-id>
</element-citation></ref><ref id="B44-ncrna-11-00032"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szklarczyk</surname><given-names>D.</given-names></name>
<name><surname>Gable</surname><given-names>A.L.</given-names></name>
<name><surname>Nastou</surname><given-names>K.C.</given-names></name>
<name><surname>Lyon</surname><given-names>D.</given-names></name>
<name><surname>Kirsch</surname><given-names>R.</given-names></name>
<name><surname>Pyysalo</surname><given-names>S.</given-names></name>
<name><surname>Doncheva</surname><given-names>N.T.</given-names></name>
<name><surname>Legeay</surname><given-names>M.</given-names></name>
<name><surname>Fang</surname><given-names>T.</given-names></name>
<name><surname>Bork</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Correction to &#x0201c;The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets&#x0201d;</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>10800</fpage><pub-id pub-id-type="doi">10.1093/nar/gkab835</pub-id><pub-id pub-id-type="pmid">34530444</pub-id>
</element-citation></ref><ref id="B45-ncrna-11-00032"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kehl</surname><given-names>T.</given-names></name>
<name><surname>Kern</surname><given-names>F.</given-names></name>
<name><surname>Backes</surname><given-names>C.</given-names></name>
<name><surname>Fehlmann</surname><given-names>T.</given-names></name>
<name><surname>St&#x000f6;ckel</surname><given-names>D.</given-names></name>
<name><surname>Meese</surname><given-names>E.</given-names></name>
<name><surname>Lenhof</surname><given-names>H.-P.</given-names></name>
<name><surname>Keller</surname><given-names>A.</given-names></name>
</person-group><article-title>miRPathDB 2.0: A novel release of the miRNA Pathway Dictionary Database</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D142</fpage><lpage>D147</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1022</pub-id><pub-id pub-id-type="pmid">31691816</pub-id>
</element-citation></ref><ref id="B46-ncrna-11-00032"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>N.W.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>OncomiR: An online resource for exploring pan-cancer microRNA dysregulation</article-title><source>Bioinformatics</source><year>2018</year><volume>34</volume><fpage>713</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx627</pub-id><pub-id pub-id-type="pmid">29028907</pub-id>
</element-citation></ref><ref id="B47-ncrna-11-00032"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.-H.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Qu</surname><given-names>L.-H.</given-names></name>
<name><surname>Yang</surname><given-names>J.-H.</given-names></name>
</person-group><article-title>starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>D92</fpage><lpage>D97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1248</pub-id><pub-id pub-id-type="pmid">24297251</pub-id>
</element-citation></ref><ref id="B48-ncrna-11-00032"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gy&#x00151;rffy</surname><given-names>B.</given-names></name>
</person-group><article-title>Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors</article-title><source>Innovation</source><year>2024</year><volume>5</volume><fpage>100625</fpage><pub-id pub-id-type="doi">10.1016/j.xinn.2024.100625</pub-id><pub-id pub-id-type="pmid">38706955</pub-id>
</element-citation></ref><ref id="B49-ncrna-11-00032"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Zeng</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title>SRplot: A free online platform for data visualization and graphing</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0294236</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0294236</pub-id><pub-id pub-id-type="pmid">37943830</pub-id>
</element-citation></ref><ref id="B50-ncrna-11-00032"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartoszewski</surname><given-names>R.A.</given-names></name>
<name><surname>Jablonsky</surname><given-names>M.</given-names></name>
<name><surname>Bartoszewska</surname><given-names>S.</given-names></name>
<name><surname>Stevenson</surname><given-names>L.</given-names></name>
<name><surname>Dai</surname><given-names>Q.</given-names></name>
<name><surname>Kappes</surname><given-names>J.</given-names></name>
<name><surname>Collawn</surname><given-names>J.F.</given-names></name>
<name><surname>Bebok</surname><given-names>Z.</given-names></name>
</person-group><article-title>A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>28741</fpage><lpage>28748</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.154575</pub-id><pub-id pub-id-type="pmid">20628052</pub-id>
</element-citation></ref><ref id="B51-ncrna-11-00032"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naslavsky</surname><given-names>M.S.</given-names></name>
<name><surname>Crovella</surname><given-names>S.</given-names></name>
<name><surname>Lima Filho</surname><given-names>J.L.</given-names></name>
<name><surname>Rocha</surname><given-names>C.R.C.</given-names></name>
</person-group><article-title>The sound of silence: Human beta-defensin-1 gene untranslated SNPs change the predicted mRNA secondary structure in a length-dependent manner</article-title><source>Immunol. Lett.</source><year>2010</year><volume>129</volume><fpage>53</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2009.12.024</pub-id><pub-id pub-id-type="pmid">20060856</pub-id>
</element-citation></ref><ref id="B52-ncrna-11-00032"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karthi</surname><given-names>S.</given-names></name>
<name><surname>Rajeshwari</surname><given-names>M.</given-names></name>
<name><surname>Francis</surname><given-names>A.</given-names></name>
<name><surname>Saravanan</surname><given-names>M.</given-names></name>
<name><surname>Varalakshmi</surname><given-names>P.</given-names></name>
<name><surname>Houlden</surname><given-names>H.</given-names></name>
<name><surname>Thangaraj</surname><given-names>K.</given-names></name>
<name><surname>Ashokkumar</surname><given-names>B.</given-names></name>
</person-group><article-title>3&#x02032;-UTR SNP rs2229611 in G6PC1 affects mRNA stability, expression and Glycogen Storage Disease type-Ia risk</article-title><source>Clin. Chim. Acta</source><year>2017</year><volume>471</volume><fpage>46</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2017.05.016</pub-id><pub-id pub-id-type="pmid">28502559</pub-id>
</element-citation></ref><ref id="B53-ncrna-11-00032"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braicu</surname><given-names>C.</given-names></name>
<name><surname>Buse</surname><given-names>M.</given-names></name>
<name><surname>Busuioc</surname><given-names>C.</given-names></name>
<name><surname>Drula</surname><given-names>R.</given-names></name>
<name><surname>Gulei</surname><given-names>D.</given-names></name>
<name><surname>Raduly</surname><given-names>L.</given-names></name>
<name><surname>Rusu</surname><given-names>A.</given-names></name>
<name><surname>Irimie</surname><given-names>A.</given-names></name>
<name><surname>Atanasov</surname><given-names>A.G.</given-names></name>
<name><surname>Slaby</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>A comprehensive review on MAPK: A promising therapeutic target in cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>1618</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11101618</pub-id><pub-id pub-id-type="pmid">31652660</pub-id>
</element-citation></ref><ref id="B54-ncrna-11-00032"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braga</surname><given-names>E.A.</given-names></name>
<name><surname>Fridman</surname><given-names>M.V.</given-names></name>
<name><surname>Loginov</surname><given-names>V.I.</given-names></name>
<name><surname>Dmitriev</surname><given-names>A.A.</given-names></name>
<name><surname>Morozov</surname><given-names>S.G.</given-names></name>
</person-group><article-title>Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes</article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><elocation-id>320</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2019.00320</pub-id><pub-id pub-id-type="pmid">31110513</pub-id>
</element-citation></ref><ref id="B55-ncrna-11-00032"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>T.</given-names></name>
<name><surname>Wong</surname><given-names>H.K.</given-names></name>
<name><surname>Gu</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>To</surname><given-names>K.-F.</given-names></name>
<name><surname>Wang</surname><given-names>C.C.</given-names></name>
<name><surname>Wong</surname><given-names>Y.F.</given-names></name>
<name><surname>Cheung</surname><given-names>T.H.</given-names></name>
<name><surname>Chung</surname><given-names>T.K.H.</given-names></name>
<name><surname>Choy</surname><given-names>K.W.</given-names></name>
</person-group><article-title>MicroRNA-182 plays an onco-miRNA role in cervical cancer</article-title><source>Gynecol. Oncol.</source><year>2013</year><volume>129</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.12.043</pub-id><pub-id pub-id-type="pmid">23313739</pub-id>
</element-citation></ref><ref id="B56-ncrna-11-00032"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Xiao</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
<name><surname>Cho</surname><given-names>C.H.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
</person-group><article-title>An overview of the multifaceted roles of miRNAs in gastric cancer: Spotlight on novel biomarkers and therapeutic targets</article-title><source>Biochem. Pharmacol.</source><year>2019</year><volume>163</volume><fpage>425</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2019.03.011</pub-id><pub-id pub-id-type="pmid">30857828</pub-id>
</element-citation></ref><ref id="B57-ncrna-11-00032"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>R.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>X.</given-names></name>
<name><surname>Zang</surname><given-names>R.</given-names></name>
</person-group><article-title>ZFPM2-AS1 transcriptionally mediated by STAT1 regulates thyroid cancer cell growth, migration and invasion via miR-515-5p/TUSC3</article-title><source>J. Cancer</source><year>2021</year><volume>12</volume><fpage>3393</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.7150/jca.51437</pub-id><pub-id pub-id-type="pmid">33976749</pub-id>
</element-citation></ref><ref id="B58-ncrna-11-00032"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.-T.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>L.</given-names></name>
<name><surname>Gan</surname><given-names>B.-L.</given-names></name>
<name><surname>Xie</surname><given-names>Z.-C.</given-names></name>
<name><surname>Zeng</surname><given-names>J.-J.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
</person-group><article-title>Role of upregulated miR-136-5p in lung adenocarcinoma: A study of 1242 samples utilizing bioinformatics analysis</article-title><source>Pathol. Res. Pract.</source><year>2018</year><volume>214</volume><fpage>750</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2018.02.017</pub-id><pub-id pub-id-type="pmid">29526559</pub-id>
</element-citation></ref><ref id="B59-ncrna-11-00032"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gramantieri</surname><given-names>L.</given-names></name>
<name><surname>Ferracin</surname><given-names>M.</given-names></name>
<name><surname>Fornari</surname><given-names>F.</given-names></name>
<name><surname>Veronese</surname><given-names>A.</given-names></name>
<name><surname>Sabbioni</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>C.-G.</given-names></name>
<name><surname>Calin</surname><given-names>G.A.</given-names></name>
<name><surname>Giovannini</surname><given-names>C.</given-names></name>
<name><surname>Ferrazzi</surname><given-names>E.</given-names></name>
<name><surname>Grazi</surname><given-names>G.L.</given-names></name>
<etal/>
</person-group><article-title>Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>6092</fpage><lpage>6099</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4607</pub-id><pub-id pub-id-type="pmid">17616664</pub-id>
</element-citation></ref><ref id="B60-ncrna-11-00032"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Assiri</surname><given-names>A.A.</given-names></name>
<name><surname>Mourad</surname><given-names>N.</given-names></name>
<name><surname>Shao</surname><given-names>M.</given-names></name>
<name><surname>Kiel</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Skaar</surname><given-names>T.C.</given-names></name>
<name><surname>Overholser</surname><given-names>B.R.</given-names></name>
</person-group><article-title>MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation</article-title><source>Cancer Genom. Proteom.</source><year>2019</year><volume>16</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.21873/cgp.20147</pub-id></element-citation></ref><ref id="B61-ncrna-11-00032"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Rho</surname><given-names>J.G.</given-names></name>
<name><surname>Seo</surname><given-names>J.W.</given-names></name>
<name><surname>Nam</surname><given-names>J.W.</given-names></name>
<name><surname>Song</surname><given-names>W.K.</given-names></name>
<name><surname>Nam</surname><given-names>S.W.</given-names></name>
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Lee</surname><given-names>E.K.</given-names></name>
</person-group><article-title>Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer</article-title><source>Cell Death Differ.</source><year>2016</year><volume>23</volume><fpage>484</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.116</pub-id><pub-id pub-id-type="pmid">26337669</pub-id>
</element-citation></ref><ref id="B62-ncrna-11-00032"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>L.L.</given-names></name>
<name><surname>Tobiasen</surname><given-names>H.</given-names></name>
<name><surname>Holm</surname><given-names>A.</given-names></name>
<name><surname>Schepeler</surname><given-names>T.</given-names></name>
<name><surname>Ostenfeld</surname><given-names>M.S.</given-names></name>
<name><surname>Thorsen</surname><given-names>K.</given-names></name>
<name><surname>Rasmussen</surname><given-names>M.H.</given-names></name>
<name><surname>Birkenkamp-Demtroeder</surname><given-names>K.</given-names></name>
<name><surname>Sieber</surname><given-names>O.M.</given-names></name>
<name><surname>Gibbs</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer</article-title><source>Int. J. Cancer</source><year>2013</year><volume>133</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/ijc.28010</pub-id><pub-id pub-id-type="pmid">23280316</pub-id>
</element-citation></ref><ref id="B63-ncrna-11-00032"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>C.</given-names></name>
<name><surname>Pan</surname><given-names>J.</given-names></name>
<name><surname>Zheng</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>MicroRNA-362-3p Inhibits Migration and Invasion via Targeting BCAP31 in Cervical Cancer</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>7</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2020.00107</pub-id><pub-id pub-id-type="pmid">32582765</pub-id>
</element-citation></ref><ref id="B64-ncrna-11-00032"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Dang</surname><given-names>E.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>Y.</given-names></name>
<name><surname>Shi</surname><given-names>J.</given-names></name>
<name><surname>Tao</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>MiR-362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGF&#x003b2;/Smad pathway</article-title><source>Cancer Med.</source><year>2021</year><volume>10</volume><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1002/cam4.3601</pub-id><pub-id pub-id-type="pmid">33210473</pub-id>
</element-citation></ref><ref id="B65-ncrna-11-00032"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Yi</surname><given-names>K.</given-names></name>
<name><surname>Hou</surname><given-names>M.</given-names></name>
</person-group><article-title>The suppressive role of miR-362-3p in epithelial ovarian cancer</article-title><source>Heliyon</source><year>2020</year><volume>6</volume><fpage>e04258</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2020.e04258</pub-id><pub-id pub-id-type="pmid">32671239</pub-id>
</element-citation></ref><ref id="B66-ncrna-11-00032"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
</person-group><article-title>miR-362-3p suppresses ovarian cancer by inhibiting LRP8</article-title><source>Transl. Oncol.</source><year>2022</year><volume>15</volume><fpage>101284</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101284</pub-id><pub-id pub-id-type="pmid">34839107</pub-id>
</element-citation></ref><ref id="B67-ncrna-11-00032"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>N.</given-names></name>
<name><surname>Liao</surname><given-names>X.</given-names></name>
</person-group><article-title>miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer</article-title><source>J. Ovarian Res.</source><year>2021</year><volume>14</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13048-020-00760-2</pub-id><pub-id pub-id-type="pmid">33526047</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="ncrna-11-00032-f001"><label>Figure 1</label><caption><p>MiRNA-gene network by miRNet. Blue square nodes represent miRNAs (source nodes), purple dots represent genes (target nodes), and yellow edges represent the interactions between nodes. The size of the blue square nodes, which represent miRNAs, indicates their significance in the network. A larger square size reflects more targeted genes by that miRNA, highlighting its potential importance in gene regulation.</p></caption><graphic xlink:href="ncrna-11-00032-g001" position="float"/></fig><fig position="float" id="ncrna-11-00032-f002"><label>Figure 2</label><caption><p>Bar plot of gene enrichment pathways by ShinyGo. The <italic toggle="yes">Y</italic>-axis represents the top 20 significant pathways. The <italic toggle="yes">X</italic>-axis represents the number of genes in the pathway.</p></caption><graphic xlink:href="ncrna-11-00032-g002" position="float"/></fig><fig position="float" id="ncrna-11-00032-f003"><label>Figure 3</label><caption><p>Protein&#x02013;protein interaction network using STRING database.</p></caption><graphic xlink:href="ncrna-11-00032-g003" position="float"/></fig><fig position="float" id="ncrna-11-00032-f004"><label>Figure 4</label><caption><p>The heat map shows the miRNA enrichment constructed by miRPathDB. Darker colors indicate stronger statistical significance (higher log <italic toggle="yes">p</italic>-values and lower <italic toggle="yes">p</italic>-values), while lighter colors suggest weaker associations (lower log <italic toggle="yes">p</italic>-values and higher <italic toggle="yes">p</italic>-values).</p></caption><graphic xlink:href="ncrna-11-00032-g004" position="float"/></fig><fig position="float" id="ncrna-11-00032-f005"><label>Figure 5</label><caption><p>Integration of expression analysis (from the StarBase database) and survival study (from the Kaplan&#x02013;Meier Plotter) of hsa-miR-362-3p and hsa-miR-136-5p. Expression and survival analysis of hsa-miR-362-3p in LIHC (<bold>A</bold>,<bold>B</bold>). Expression and survival analysis of hsa-miR-136-5p in BLCA (<bold>C</bold>,<bold>D</bold>), LUSC (<bold>E</bold>,<bold>F</bold>), and STAD (<bold>G</bold>,<bold>H</bold>).</p></caption><graphic xlink:href="ncrna-11-00032-g005a" position="float"/><graphic xlink:href="ncrna-11-00032-g005b" position="float"/></fig><fig position="float" id="ncrna-11-00032-f006"><label>Figure 6</label><caption><p>The Sankey diagram illustrates the relationships between SNPs (rs114360225 and rs190542524), the potential oncogenic miRNAs (hsa-miR-362-3p and hsa-miR-136-5p), and their corresponding cancer types.</p></caption><graphic xlink:href="ncrna-11-00032-g006" position="float"/></fig><fig position="float" id="ncrna-11-00032-f007"><label>Figure 7</label><caption><p>Workflow of the study.</p></caption><graphic xlink:href="ncrna-11-00032-g007" position="float"/></fig><table-wrap position="float" id="ncrna-11-00032-t001"><object-id pub-id-type="pii">ncrna-11-00032-t001_Table 1</object-id><label>Table 1</label><caption><p>3&#x02032; UTR SNPs created new miRNA-binding sites and their corresponding miRNAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNP ID</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miRNAs</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs11305</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-6504-3p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs184180073</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-4287, hsa-miR-4685-3p, hsa-miR-5088-3p, hsa-miR-6734-3p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41363648</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-134-3p, hsa-miR-4778-5p, hsa-miR-7114-5p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs188557905</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-4699-3p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs186033487</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-122-3p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs79073086</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-4766-5p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs114360225</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-216b-3p, hsa-miR-329-3p, hsa-miR-362-3p, hsa-miR-3941, hsa-miR-603</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs139958571</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-6814-3p, hsa-miR-6872-5p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs182394503</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-202-5p, hsa-miR-337-3p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs190542524</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-136-5p, hsa-miR-515-5p, hsa-miR-519e-5p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs182725919</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-6741-5p</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41481847</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-3148, hsa-miR-3162-5p, hsa-miR-4668-5p, hsa-miR-5584-5p, hsa-miR-6750-5p, hsa-miR-6822-5p</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ncrna-11-00032-t002"><object-id pub-id-type="pii">ncrna-11-00032-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparison between the wild-type and mutant mRNA structures of the predicted 3&#x02032; UTR SNPs that create new miRNA binding sites using the RNAfold server.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNP ID </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Minimum Free Energy of Wild Type kcal/mol </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Wild mRNA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Minimum Free Energy of Mutant Type kcal/mol</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mutant mRNA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Interpretation</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs114360225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;17.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i002.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A reduction in MFE in the mutant mRNA induces structural alterations in the mRNA, hence stabilizing its structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs139958571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i003.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i004.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41363648</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i005.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i006.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41481847</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;21.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i007.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;26.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i008.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A reduction in MFE in the mutant mRNA induces structural alterations in the mRNA, hence stabilizing its structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs11305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i009.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i010.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs184180073</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i011.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i012.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs79073086</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i013.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i014.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A reduction in MFE in the mutant mRNA induces structural alterations in the mRNA, hence stabilizing its structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41363648</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i015.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i016.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs186033487 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i017.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i018.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A reduction in MFE in the mutant mRNA induces structural alterations in the mRNA, hence stabilizing its structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs188557905</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;35.80 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i019.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;13.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i020.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The energy elevation destabilizes the mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs139958571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i021.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i022.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No alteration in energy, accompanied by no alteration in mRNA structure.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs190542524</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;23.80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i023.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;22.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="ncrna-11-00032-i024.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The energy elevation destabilizes the mRNA structure.</td></tr></tbody></table><table-wrap-foot><fn><p>Structures are color-annotated to indicate base-pairing probabilities. The highest probabilities are red (&#x02265;99%), orange (99% &#x0003e; probability &#x02265; 95%), yellow (95% &#x0003e; probability &#x02265; 90%), dark green (90% &#x0003e; probability &#x02265; 80%), light green (80% &#x0003e; probability &#x02265; 70%), light blue (70% &#x0003e; probability &#x02265; 60%), dark blue (60% &#x0003e; probability &#x02265; 50%), and purple (&#x02264;50%).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ncrna-11-00032-t003"><object-id pub-id-type="pii">ncrna-11-00032-t003_Table 3</object-id><label>Table 3</label><caption><p>The predicted oncogenic 3&#x02032; UTR SNPs of the STAT1 gene by CScape.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SNP ID </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chromosomal Location</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cscape Score</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Interpretation </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs114360225</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,190970130,T,C </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.468060</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benign</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs139958571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191835001,C,G </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.589398</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41363648</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834487,T,C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.686973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41481847</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191835275,A,G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.527544</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs11305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834030,T,A<break/>2,191834030,T,C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.707913<break/>0.516490</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic<break/>Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs184180073</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834477,T,C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.667051</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs79073086</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834832,G,A<break/>2,191834832,G,C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.666260<break/>0.596381</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic<break/>Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs41363648</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834487,T,C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.686973</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs186033487 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834759,A,C<break/>2,191834759,A,G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.717679<break/>0.672660</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic<break/>Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs188557905</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191834574,C,T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.753580</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs139958571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191835001,C,G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.589398</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rs190542524</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,191835125,T,A <break/>2,191835125,T,C<break/>2,191835125,T,G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.802671<break/>0.534609<break/>0.746269</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncogenic<break/>Oncogenic<break/>Oncogenic</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ncrna-11-00032-t004"><object-id pub-id-type="pii">ncrna-11-00032-t004_Table 4</object-id><label>Table 4</label><caption><p>Differential expression profile of miRNAs in cancer by oncoMIR.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">miRNAs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer Type </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Upregulated in </th></tr></thead><tbody><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">hsa-miR-362-3p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BLCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.86 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.61 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.07 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIRC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.77 &#x000d7; 10<sup>&#x02212;8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.08 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LIHC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.37 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.55 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.12 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.17 &#x000d7; 10<sup>&#x02212;5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UCEC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.49 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">hsa-miR-136-5p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BLCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.01 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.39 &#x000d7; 10<sup>&#x02212;4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.36 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIRC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51 &#x000d7; 10<sup>&#x02212;14</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KIRP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09&#x000d7; 10<sup>&#x02212;11</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LIHC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.47&#x000d7; 10<sup>&#x02212;11</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUAD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.05 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.51 &#x000d7; 10<sup>&#x02212;6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.54 &#x000d7; 10<sup>&#x02212;7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hsa-miR-515-5p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LUAD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.89 &#x000d7; 10<sup>&#x02212;2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">hsa-miR-329-3p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BRCA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.22 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HNSC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.42 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Normal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STAD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.45 &#x000d7; 10<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor</td></tr></tbody></table><table-wrap-foot><fn><p>BLCA: bladder carcinoma; BRCA: breast invasive carcinoma; HNSC: head and neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LUSC: lung squamous cell carcinoma; STAD: stomach adenocarcinoma; THCA: thyroid carcinoma; UCEC: uterine corpus endometrial carcinoma.</p></fn></table-wrap-foot></table-wrap></floats-group></article>